Site content: Global

Press Release

2024 - 1 - 16

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

STIC CTC trial data published this November 2023 in the Journal of Clinical Oncology (JCO) demonstrate that CTC-guided treatment decision confers superior survival benefits in a subgroup...
Read more

2024 - 1 - 9

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

Results published by the DETECT study group indicate the relevance of assessing biomarker expression in Circulating Tumor Cells (CTCs) with the minimally invasive liquid biopsy-based...
Read more

2023 - 10 - 3

Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma

Results of this MD Anderson study were recently published in Cancers and indicate the relevance of enumeration of Circulating Tumor Cells (CTCs) with the minimally invasive liquid...
Read more

2023 - 5 - 17

New Menarini Silicon Biosystems partnership with Alivio Health expands patient access to CELLSEARCH® liquid biopsy tests

Menarini Silicon Biosystems just signed a partnership with Alivio Health to provide preferred access, to their clients and members, to the minimally invasive CELLSEARCH® CTC tests so...
Read more

2022 - 12 - 22

New STIC trial data shows longer overall survival for therapy selection based on CELLSEARCH® CTC count in patients with metastatic breast cancer

Integration of CTC (Circulating Tumor Cell) enumeration* to decide between endocrine therapy and chemotherapy may lead to improved clinical outcomes and quality of life for patients with...
Read more

2022 - 12 - 14

Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early

Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the...
Read more

2022 - 10 - 13

Menarini Silicon Biosystems’s CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination

These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2)...
Read more

2021 - 12 - 14

Menarini Silicon Biosystems Announces study results to be presented at American Society of Hematology (ASH) Annual Meeting

Menarini Silicon Biosystems Announces study results to be presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCH® CMMC assay, a Non-Invasive...
Read more

2021 - 11 - 30

New CELLSEARCH® Circulating Multiple Myeloma Test now available to help community physicians optimize patient care

As the market leader in cell-based liquid biopsies, Menarini Silicon Biosystems is offering community hematology-oncologists an opportunity to have patient blood samples sent to a US...
Read more
123